{"id":16549,"date":"2020-06-19T06:00:05","date_gmt":"2020-06-19T05:00:05","guid":{"rendered":"https:\/\/fight-malaria-blog.local\/?p=16549"},"modified":"2020-06-17T22:57:27","modified_gmt":"2020-06-17T21:57:27","slug":"mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial","status":"publish","type":"post","link":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/","title":{"rendered":"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial"},"content":{"rendered":"<h5><strong>The Latest Malaria News, in 60 Seconds.<\/strong><\/h5><p>Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by <em>Anopheles gambiae<\/em> mosquitoes.<\/p><!--[if lt IE 9]><script>document.createElement('audio');<\/script><![endif]-->\n<audio class=\"wp-audio-shortcode\" id=\"audio-16549-1\" autoplay=\"1\" preload=\"none\" style=\"width: 100%;\" controls=\"controls\"><source type=\"audio\/mpeg\" src=\"https:\/\/d3ctxlq1ktw2nl.cloudfront.net\/staging\/2020-5-17\/83122516-44100-2-fcf9d1b6ac272.m4a?_=1\" \/><a href=\"https:\/\/d3ctxlq1ktw2nl.cloudfront.net\/staging\/2020-5-17\/83122516-44100-2-fcf9d1b6ac272.m4a\">https:\/\/d3ctxlq1ktw2nl.cloudfront.net\/staging\/2020-5-17\/83122516-44100-2-fcf9d1b6ac272.m4a<\/a><\/audio><p>Malaria Minute on <a href=\"https:\/\/itunes.apple.com\/gb\/podcast\/malaria-minute\/id1355091623\" target=\"_blank\" rel=\"noreferrer noopener\">iTunes<\/a> and <a href=\"https:\/\/open.spotify.com\/show\/5ucD00RxBqAaf29Km7lFOI\" target=\"_blank\" rel=\"noreferrer noopener\">Spotify<\/a><\/p><hr \/><h5><strong>Transcript:<\/strong><\/h5><p>Whilst many of the vaccine candidates against malaria aim to provide protection against <em>Plasmodium<\/em> parasites, to date there has not been a vaccine evaluated in humans targeted towards the mosquito itself. Preclinical studies have suggested that antibodies to mosquito saliva may provide some protection against mosquito-borne diseases, and this could also apply to malaria. In a new clinical trial, researchers assessed the immunogenicity of the AGS-v vaccine, which aims to induce antibodies against saliva produced by <em>Anopheles gambiae<\/em>, the main malaria vector in Africa. 49 participants were assigned to either a vaccine-only group, an adjuvanted vaccine group or a placebo group. The vaccine was well-tolerated in all cases and most immunogenic when given with adjuvant, resulting in a significant increase in vaccine-specific IgG antibodies and also the cytokines interferon-gamma. If the vaccine provides protection, it could help to control malaria.<\/p><h5><strong>Sources:<\/strong><\/h5><p class=\"highwire-cite-title\"><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(20)31048-5\" target=\"_blank\" rel=\"noopener noreferrer\">Safety and Immunogenicity of a Mosquito Saliva Peptide-Based Vaccine: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Trial<\/a><\/p><p><!-- \/wp:paragraph --><\/p><hr \/><p><strong>Image Credits:\u00a0<\/strong>CDC\/ James Gathany [<a href=\"https:\/\/phil.cdc.gov\/Details.aspx?pid=18754\" target=\"_blank\" rel=\"noopener noreferrer\">18754<\/a>]<!-- wp:paragraph --><\/p><p><strong>Scientific Advisor:<\/strong> Katharine Collins, Radboud University Medical Centre<\/p>","protected":false},"excerpt":{"rendered":"<p>Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by Anopheles gambiae mosquitoes.<\/p>\n","protected":false},"author":1,"featured_media":16550,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[9],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.14 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial - The Fight Malaria Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial - The Fight Malaria Blog\" \/>\n<meta property=\"og:description\" content=\"Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by Anopheles gambiae mosquitoes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"The Fight Malaria Blog\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-19T05:00:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-17T21:57:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/06\/Mosquito-Saliva-Vaccine-Evaluated-in-Phase-1-Clinical-Trial.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Thomas Locke\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Thomas Locke\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/\"},\"author\":{\"name\":\"Thomas Locke\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/866d37307e013f5a16202221b93ef75a\"},\"headline\":\"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial\",\"datePublished\":\"2020-06-19T05:00:05+00:00\",\"dateModified\":\"2020-06-17T21:57:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/\"},\"wordCount\":226,\"publisher\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/#organization\"},\"articleSection\":[\"Malaria Minute\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/\",\"url\":\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/\",\"name\":\"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial - The Fight Malaria Blog\",\"isPartOf\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/#website\"},\"datePublished\":\"2020-06-19T05:00:05+00:00\",\"dateModified\":\"2020-06-17T21:57:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fight-malaria-blog.local\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#website\",\"url\":\"https:\/\/fight-malaria-blog.local\/\",\"name\":\"The Fight Malaria Blog\",\"description\":\"Malaria News, Views and Interviews.\",\"publisher\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fight-malaria-blog.local\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#organization\",\"name\":\"Fight Malaria\",\"url\":\"https:\/\/fight-malaria-blog.local\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/07\/blog_logo-20200728-212450.svg\",\"contentUrl\":\"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/07\/blog_logo-20200728-212450.svg\",\"caption\":\"Fight Malaria\"},\"image\":{\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/866d37307e013f5a16202221b93ef75a\",\"name\":\"Thomas Locke\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4e07b1fc2fb741436038290480c02087?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4e07b1fc2fb741436038290480c02087?s=96&d=mm&r=g\",\"caption\":\"Thomas Locke\"},\"url\":\"https:\/\/fight-malaria-blog.local\/author\/fightmalaria\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial - The Fight Malaria Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/","og_locale":"en_GB","og_type":"article","og_title":"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial - The Fight Malaria Blog","og_description":"Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by Anopheles gambiae mosquitoes.","og_url":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/","og_site_name":"The Fight Malaria Blog","article_published_time":"2020-06-19T05:00:05+00:00","article_modified_time":"2020-06-17T21:57:27+00:00","og_image":[{"width":800,"height":500,"url":"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/06\/Mosquito-Saliva-Vaccine-Evaluated-in-Phase-1-Clinical-Trial.png","type":"image\/png"}],"author":"Thomas Locke","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Thomas Locke","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/"},"author":{"name":"Thomas Locke","@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/866d37307e013f5a16202221b93ef75a"},"headline":"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial","datePublished":"2020-06-19T05:00:05+00:00","dateModified":"2020-06-17T21:57:27+00:00","mainEntityOfPage":{"@id":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/"},"wordCount":226,"publisher":{"@id":"https:\/\/fight-malaria-blog.local\/#organization"},"articleSection":["Malaria Minute"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/","url":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/","name":"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial - The Fight Malaria Blog","isPartOf":{"@id":"https:\/\/fight-malaria-blog.local\/#website"},"datePublished":"2020-06-19T05:00:05+00:00","dateModified":"2020-06-17T21:57:27+00:00","breadcrumb":{"@id":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fight-malaria-blog.local\/malaria-minute\/mosquito-saliva-vaccine-evaluated-in-phase-1-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fight-malaria-blog.local\/"},{"@type":"ListItem","position":2,"name":"Mosquito Saliva Vaccine Evaluated in Phase 1 Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/fight-malaria-blog.local\/#website","url":"https:\/\/fight-malaria-blog.local\/","name":"The Fight Malaria Blog","description":"Malaria News, Views and Interviews.","publisher":{"@id":"https:\/\/fight-malaria-blog.local\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fight-malaria-blog.local\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/fight-malaria-blog.local\/#organization","name":"Fight Malaria","url":"https:\/\/fight-malaria-blog.local\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/logo\/image\/","url":"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/07\/blog_logo-20200728-212450.svg","contentUrl":"https:\/\/fight-malaria-blog.local\/wp-content\/uploads\/2020\/07\/blog_logo-20200728-212450.svg","caption":"Fight Malaria"},"image":{"@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/866d37307e013f5a16202221b93ef75a","name":"Thomas Locke","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/fight-malaria-blog.local\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4e07b1fc2fb741436038290480c02087?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4e07b1fc2fb741436038290480c02087?s=96&d=mm&r=g","caption":"Thomas Locke"},"url":"https:\/\/fight-malaria-blog.local\/author\/fightmalaria\/"}]}},"_links":{"self":[{"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/posts\/16549"}],"collection":[{"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/comments?post=16549"}],"version-history":[{"count":0,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/posts\/16549\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/media\/16550"}],"wp:attachment":[{"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/media?parent=16549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/categories?post=16549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fight-malaria-blog.local\/wp-json\/wp\/v2\/tags?post=16549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}